Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8

Background: Basal insulin peglispro (BIL) has a peripheral-to-hepatic distribution of action that resembles endogenous insulin and a prolonged duration of action with a flat pharmacokinetic/pharmacodynamic profile at steady state, characteristics that tend to reduce hypoglycemia risk compared to ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Cynthia, Forst, Thomas, Heise, Tim, Plum-Mörschel, Leona, Watkins, Elaine, Zhang, Qianyi, Fan, Ludi, Garhyan, Parag, Porksen, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567880/
https://www.ncbi.nlm.nih.gov/pubmed/28817342
http://dx.doi.org/10.1089/dia.2016.0414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567880/
https://www.ncbi.nlm.nih.gov/pubmed/28817342
http://dx.doi.org/10.1089/dia.2016.0414

Ejemplares similares